Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by Lee430on Oct 14, 2023 12:28pm
75 Views
Post# 35683698

RE:RE:Trading

RE:RE:Trading Well I am HOPING the reason for the lack of insider buying & options being extended is pending deals maybe waiting for PH1 results or first signs of good results maybe.

PWIB123 wrote: Several days of extremely low trading crushed the stock.  

All I can say is that we appear to be on our last hope that cancer will be everything we hope it to be.  Hope isn't a strategy, and that's apparent in the stock price.  THTX has missed on every potential so far.  Doesn't give you a lot of hope on cancer.  I've accepted the fact that I'm probably going to lose the $250K I'm down when it comes time to move on to something else.  At least I'll have the losses to carryforward against future capital gains.  Hope is now my strategy.  It's becoming more and more obvious that no one is going to value the legacy drugs at anything meaningful, at least not with the current leadership team.  I'm just hoping that somehow THTX pulls off a miracle with the oncology trial and gets incredible results.  

Still no insider buying.



<< Previous
Bullboard Posts
Next >>